Clinical Trials in Washington

Showing 5961-5980 of 7,241 trials

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849

The aim of this study is to assess the long-term safety of exenatide in patients with type 2 diabetes who were treated with exenatide in Study H8O-MC-GWAA (6-month study) or Study H8O-MC-GWAD (12-month study). Study H8O-MC-GWAN serves as an open-ended extension to Studies H8O-MC-GWAA and H8O-MC-GWAD.

Type 2 Diabetes Mellitus

AstraZeneca275 participantsStarted Dec 2003

Renton, Washington, United States

COMPLETEDPhase 334 miles

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

NCT00039026

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.

Diabetes Mellitus, Non-Insulin-Dependent

AstraZeneca377 participantsStarted Feb 2002

Anniston, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +123 more locations

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Find Trials by Condition in Washington

Extension Study for 2993-112

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)